Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Perkovic V, Tuttle KR, Rossing P, et al. New England Journal of Medicine 2024;391:109-121.
What it found
Major kidney events (kidney failure, a 50% fall in kidney function, or death from kidney or cardiovascular causes) were 24% less frequent with semaglutide (hazard ratio 0.76). Kidney function declined more slowly, and cardiovascular events and deaths from any cause were also lower. Serious adverse events: 49.6% vs 53.8%.
Limitations
People with type 2 diabetes and chronic kidney disease only. Trials stopped early can overestimate the size of a benefit.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.